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Abstract
Methamphetamine (METH) addiction is associated with several neuropsychiatric symptoms. Little is known about the effects
of METH on gene expression and epigenetic modifications in the rat nucleus accumbens (NAC). Our study investigated the
effects of a non-toxic METH injection (20 mg/kg) on gene expression, histone acetylation, and the expression of the histone
acetyltransferase (HAT), ATF2, and of the histone deacetylases (HDACs), HDAC1 and HDAC2, in that structure. Microarray
analyses done at 1, 8, 16 and 24 hrs after the METH injection identified METH-induced changes in the expression of genes
previously implicated in the acute and longterm effects of psychostimulants, including immediate early genes and
corticotropin-releasing factor (Crf). In contrast, the METH injection caused time-dependent decreases in the expression of
other genes including Npas4 and cholecystokinin (Cck). Pathway analyses showed that genes with altered expression
participated in behavioral performance, cell-to-cell signaling, and regulation of gene expression. PCR analyses confirmed the
changes in the expression of c-fos, fosB, Crf, Cck, and Npas4 transcripts. To determine if the METH injection caused post-
translational changes in histone markers, we used western blot analyses and identified METH-mediated decreases in histone
H3 acetylated at lysine 9 (H3K9ac) and lysine 18 (H3K18ac) in nuclear sub-fractions. In contrast, the METH injection caused
time-dependent increases in acetylated H4K5 and H4K8. The changes in histone acetylation were accompanied by
decreased expression of HDAC1 but increased expression of HDAC2 protein levels. The histone acetyltransferase, ATF2,
showed significant METH-induced increased in protein expression. These results suggest that METH-induced alterations in
global gene expression seen in rat NAC might be related, in part, to METH-induced changes in histone acetylation
secondary to changes in HAT and HDAC expression. The causal role that HATs and HDACs might play in METH-induced
gene expression needs to be investigated further.
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Introduction
Addiction to methamphetamine (METH) is an international
public health problem with an estimated 15–16 million users
worldwide. The drug is abused because it is easy to manufacture
and is cheaply available [1]. Acute administration of a range of
METH doses results in a sense of euphoria, increased energy, and
hypersexuality [2]. The acute effects can last for several hrs
because of the long elimination half-life and the metabolite profiles
of the drug [3]. Injection of the drug to rodents causes increased
locomotor activity and stereotypic behaviors [4,5] that are related,
in part, to increased levels of dopamine (DA) in the synaptic cleft of
brain regions such as the nucleus accumbens (NAC) and the
striatum[6] that receive dopaminergic projections from midbrain
DA neurons [7]. The drug also causes substantial changes in gene
expression in some brain regions including the cortex, the dorsal
striatum, and the midbrain [8,9,10,11]. These molecular changes
include transient increases and decreases in the expression of
various transcription factors, neuropeptides, and genes that
participate in several biological functions [8,9,10,11,12,13].
Gene transcription is regulated by complex interactions of
transcription factors with regulatory elements [14,15]. During
resting states, DNA is compacted in a way that interferes with the
binding of transcription factors whereas DNA becomes more
accessible during activation of cells by various stimuli [16]. DNA is
indeed packaged into chromatin whose fundamental subunit, the
nucleosome,ismade of 4corehistones,histonesH2A, H2B, H3, and
H4 that form an octomer (2 of each histone) surrounded by 146 bp
of DNA [17]. The N-tails of histones possess lysine residues that can
be reversibly acetylated or deacetylated by several histone acetyl-
transferases(HATs)orbyhistonedeacetylases(HDACs),respectively
[18,19]. Other histone modifications that can impact gene
expression include methylation, phosphorylation and ubiquitylation
[20,21,22]. These changes promote alterations in gene expression by
modifying chromatin conformation and enabling or inhibiting
recruitment of regulatory factors onto DNA sequences [23].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34236Therefore, the findings of METH-induced differential changes
in gene expression had suggested to us that the drug might also
cause changes in histone modifications. In the present study, we
focused our attention on whether a single METH injection
(20 mg/kg) that induces substantial changes in gene expression
might also alter the status of histone acetylation in the rat nucleus
accumbens (NAC). Herein, we report that METH administration
does trigger time-dependent modifications in the acetylation of
histones H3 and H4 as well as increases in ATF2 and HDAC2
expression in the NAC. We discuss the possibility that alterations
in histone acetylation might, in part, influence METH-induced
changes in gene expression in that brain structure. More direct
evidence for a specific role of these histone modifications in
mediating METH-induced effects will await further studies using
chromatin immuprecipitation followed by massive parallel se-
quencing (ChIP-Seq) [24,25].
Results
METH induces changes in gene expression in the NAC
We performed microarray analyses using Rat Illumina arrays
that contain 22, 523 probes to identify genes that are differentially
affected at 1, 8, 16, and 24 hrs after a single METH (20 mg/kg)
injection that does not cause terminal degeneration in the rat [6].
As expected the METH injection caused significant changes in
gene expression in the NAC. Figure 1 shows a Venn diagram
depicting the overlap of genes that are altered by METH at the
four time points. There were METH-induced changes in
expression of 292 genes, with 165 being up-regulated and 127
being down-regulated at the 1-hr time point. IPA analyses
revealed that they belong to classes of genes involved in behavioral
responses, cell death, cellular development and morphology,
cellular growth and proliferation, nervous system development
and function, and regulation of gene expression. Figure 2A shows
a network of affected genes that are involved in the control of gene
expression, cellular growth and proliferation, as well as endocrine
functions while Fig. 2B shows genes that are involved cell
signaling, cellular development, and nervous system development.
Genes of interest include corticotrophin releasing factor (Crf), early
growth response 1 (Egr1), early growth response 2 (Egr2), c-fos,
homer2, junB, neuronal PAS domain protein 4 (Npas4), nuclear
receptor subfamily 4 (Nr4a3), among others (see Table S1 for a
longer list).
We used qPCR to confirm the changes in 4 members of the
AP1 family of immediate early genes (IEGs). Figure 3 shows that
the METH injection caused significant increases [F (6, 26)=15.30,
p,0.0001] in c-fos mRNA levels that were already apparent at 1-
hr, peaked at 2-hr (13.6-fold) post-drug injection, and then tapered
towards normal 24 hrs later (Fig. 3A). FosB expression also
showed METH-mediated increases [F=12.65, p,0.0001] which
were obvious after 1-hr (10.2-fold), peaked at 2-hrs (13.4-fold) after
the drug injection, and then reverted back to normal by 24-hr after
the drug injection (Fig. 3B). METH caused smaller increases
[F=20.53; p,0.0001] in c-jun expression that peaked at 1-hr (2.5-
fold) and then returned to normal levels 8 hrs later (Fig. 3C).
There were also METH-induced increases [F=15.55, p,0.0001]
in junB mRNA levels which peaked at 1-hr (10.5-fold) and then
tapered towards normal 24 hrs later (Fig. 3D).
In order to identify genes that were affected by METH at later
time points, we also performed microarray analyses using tissues
from animals euthanized at 8, 16, and 24 hrs after the METH
injection. Figure 1 shows the overlap of differentially expressed
genes at these three time points. Tables S2, S3, S4 show partial
lists of the affected genes. In contrast to the 1-hr time point when
more genes showed up-regulation by METH, there were more
genes that were down-regulated from 8 to 24 hrs after the single
METH injection. For example, there were a total of 304
differentially expressed genes at the 8-hr time point, with 151
being up-regulated and 153 being down-regulated by METH.
Pathway analyses revealed that these genes participate in several
molecular and cellular functions including cell-to-cell signaling,
small molecule biochemistry, and cell death pathways. Some of the
genes are also known to participate in behavioral performance,
and tissue morphology. Figure S1 shows associated networks that
include genes for lipid metabolism, molecular transport, and
cellular compromise. Among the METH-regulated genes at the 8-
hr time-point were Crf, follistatin (Fst), inhibin beta A (InhbA), and
neuromedin U (Nmu) (Table S2). At the 16-hr time after drug
injection, 170 genes were affected by METH, with 74 being up-
and 96 being down-regulated. These genes are known to
participate in several biological functions including protein
synthesis, cell signaling, and nervous system development. Figure
S2 shows a network that contains genes related to cellular
assembly and organization, cellular movement, and nervous
system function. At 16 hrs post-drug, genes of interest that show
up-regulation included tumor necrosis factor superfamily alpha
(TNF-alpha), and Nmu (Table S3). At the 24-hr time point,
METH caused differential expression in 197 genes, with 63 being
up- and 134 being down-regulated. These genes belong to classes
of genes that participate in cell signaling, molecular transport, and
nervous system development. Figure S3 shows a network that
contain genes involved in cellular growth and proliferation, cell
death, nervous system development, and behavior. Down-
regulated genes include BDNF, Cck, Npas4, among others (Table
S4). As shown in Figure 1, there were 14 genes that were affected
at both the 1- and 8-hr time point. These genes that include Crf
participate in endocrine system function, and lipid metabolism.
There were 35 genes that were similarly affected at both 8- and
16-hr after the METH injection. IPA shows that these genes
regulated cellular development, cellular compromise, and cell-to-
cell signaling. In addition, 29 genes were similarly affected at the
16- and 24-hr time points. These are involved in cell-to-cell
signaling, developmental disorders, molecular transport, and the
regulation of gene expression.
Figure 1. A single injection of METH (20 mg/kg) caused time-
dependent changes in gene expression in the NAC. The Venn
diagram depicts the overlap of genes identified in the four time points
(1-hr, 8-hr, 16-hr and 24-hr) after administration of a single, non-toxic
dose (20 mg/kg) of METH. RNA was extracted from NAC and the
microarray experiments were performed as described in the methods
section. Genes were identified as significantly changed if they show
greater than 61.7-fold changes at p,0.05.
doi:10.1371/journal.pone.0034236.g001
METH-Induced Alterations in Histone Acetylation
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34236METH-Induced Alterations in Histone Acetylation
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34236Quantitative PCR confirmed the METH-induced changes in
the expression of some genes of interest (Fig. 3). As shown in
Fig. 3E, METH caused time-dependent increases [F (6, 30)=3.39;
p,0.0114] in Crf expression that was apparent at 1-hr (2.5-fold),
peaked at 4-hr (3.7-fold), was still elevated at 8-hr (3-fold) and then
began to revert towards normal thereafter. Figure 3F showed that
METH caused significant changes [F=14.36; p,0.0001] in the
expression of NmU that appeared at 2-hr (2-fold), peaked at 8-hr
(4.6-fold), and returned to normal values by 24-hr after the drug
injection. Consistent with the microarray results, METH caused
marked decreases [F (6, 29)=8.72; p,0.001] in Cck expression in
the nucleus accumbens (Fig. 3G). Interestingly, the decreases
occurred as early as 2 hrs (248%), remained low, and reached a
nadir (271%) by 16-hr after the drug injection. Figure 3H shows
that the injection of METH caused significant changes [F (6,
27)=4.65; p=0.0023] in Npas4 expression. Post-hoc analyses
revealed that METH caused rapid and very transient increases
(1.8-fold) at 1-hr but delayed decreases (281%) at the 24-hr time-
point (Fig. 3H).
METH-induces differential expression of acetylation
status of histones H3 and H4 in the rat NAC
Because changes in gene expression are regulated by histone
modifications, in the present study, we tested the possibility that
the METH injection might also cause rapid changes in histone
acetylation that might parallel the changes in gene expression. We
thus used western blot analyses to measure the acetylation status of
histones H3 and H4 using specific antibodies against H3
acetylated at lysine 9 (H3K9ac) or at lysine 18 (H3K18ac) and
against histone H4 acetylated at lysine 5 (H4K5ac), lysine 8
(H4K8ac), or lysine 16 (H4K16ac). The METH injection caused
significant time-dependent decreases [F (6, 26)=6.12, p,0.0004]
in H3K9 acetylation in nuclear fractions of the NAC (Fig. 4A).
The decreases were apparent at 1-hr (254%), reached 285%, and
persisted at the 24-hr time point (290%) (Fig. 4B). The METH
injections also caused significant decreases [F=6.58, p,0.0001] in
H3K18 acetylation (Fig. 4C). The decreases became obvious by 8-
hr (249%) and stayed at those low levels (Fig. 4D). Figure 5 shows
that the METH injection was associated with significant increases
[F (6, 30)=18.24, p,0.0001] in H4K5 acetylation in these
nuclear fractions (Fig. 5A). The increases occurred as early as 1-hr
(279%), increased to 841% by 8 hrs, and were still very high
(1904%) at 24 hrs after the METH injection (Fig. 5B). The
METH injection also caused significant increases [F=3.09,
p=0.0159] in H4K8 acetylation levels (Fig. 5C). The changes
first appeared at 16 hrs (282%) and stayed elevated (279%) at the
24-hr time point (Fig. 5D). Figure S4 shows the effects of METH
on the acetylation status of H4K16. The METH injection also
caused significant decreases [F (6, 33)=16.16, p,0.0001] in
H4K16 acetylation levels (Fig. S4A). The changes first appeared at
1-hr (297%) and stayed decreased (range of 285–96%) for 16 hrs,
and reverted to normal at the 24-hr time point (Fig. S4B).
METH-induced changes in HAT and HDAC protein levels
in the NAC
Histone acetylation is regulated by a balance in HAT and
HDAC expression [19,26,27]. In addition, gene induction by
psychostimulants in the brain involves, in part, a cascade that
includes phosphorylation of CREB to pCREB (see Cadet et al.
[11] for review). Our analyses showed that METH caused
significant changes [F (6, 17)=9.48, p,0.0001] in pCREB
protein expression, with prominent decreases occurring at the
24-hr time point (283%) (Fig. 6A and 6B). Because ATF2, a
member of the ATF/CREB family, has been reported to cause
acetylation of histone H4 [28], we also measured the protein levels
of ATF2. Figure 6C shows that METH caused significant
increases [F (6, 16)=7.49, p=0.0006] in ATF2 protein levels.
The increases were apparent as early as 1-hr (179%), peaked at
16 hrs (239%), and then normalized by 24 hrs after the single
METH injection (Fig. 6D). Because METH caused decreased
acetylation of histone H3K9, H3K18, and H4K16, we also
measured the protein expression of HDAC1 and HDAC2 in
nuclear fractions of the NAC (Fig. 7). Figure 7A shows the effects
of METH on HDAC1 expression. There were significant METH-
induced decreases [F (6, 18)=7.76, p=0.0003] in HDAC1
protein levels that were apparent at 1-hr (239%), reached the
lowest levels (281%) at 8 hrs, and returned towards normal
(220%) at 24 hrs after the injection (Fig. 7B). Figure 7C shows
that there were significant increases [F (6, 17)=31.03; p,0.0001]
in HDAC2 protein levels that were first apparent at 4 hrs (217%),
reached a peak at 8 hrs (339%) and were still elevated (197%) at
24 hrs after the drug injection (Fig. 7D).
Discussion
Recent studies have shown that a single administration of
METH can have prolonged behavioral, biochemical, and
molecular effects in rodents [6,12,13,29]. However, the molecular
underpinnings for these long-term effects of this drug have yet to
be fully elucidated. As an initial step in a program of studies to
clarify the molecular bases of METH-induced complex changes in
the brain, the present study investigated the time course of
potential METH-induced changes in gene expression and histone
modifications in the NAC, a structure that is closely tied to the
behavioral effects of psychostimulants [30]. We thus used a dose of
METH that does not cause any persistent toxicity in the brain [6]
to measure potential prolonged global changes in gene expression
in that structure.
Among other genes, we identified Crf as one gene that was
substantially induced in the NAC. CRF, a polypeptide composed
of 41 amino acids, is the major regulator of the pituitary-adrenal
axis [31]. CRF has been shown to trigger various biochemical and
behavioral changes in animals [32,33,34]. For example, infusion of
CRF by itself into the NAC caused increased locomotor activity
[35]. The behavioral effects are most probably due to the
widespread distribution of CRF and of its receptors in the
mammalian brain [36,37,38,39]. The acute METH-induced
increases in Crf expression are interesting because dysregulation
of processes regulated by CRF have been implicated in addiction
to illicit drugs [32,40]. Our results are also consistent with the
report that binge cocaine administration can also cause increases
in Crf in rat brain [41] and suggest that psychostimulants of
diverse classes can cause increases in Crf mRNA levels. Of related
interest, low doses of CRF can potentiate stereotypic behaviors
caused by amphetamine [42], suggesting an additional role of
Figure 2. Networks of METH-induced changes in gene expression one hour after the drug injection. Networks of related genes were
identified using Ingenuity Pathway Analysis (IPA) software. Figure 2A shows a network of affected genes that are involved in the control of gene
expression, cellular growth and proliferation as well as endocrine functions while Fig. 2B shows genes that are involved in that are involved cell
signaling, cellular development, and nervous system development. Relationships are shown as lines and arrows. Genes colored pink to red are up-
regulated whereas those colored light to deep green are down-regulated, with the intensity of the color representing greater magnitude of changes.
doi:10.1371/journal.pone.0034236.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34236Figure 3. METH caused changes in the expression of transcription factors and neuropeptides in the NAC. The graphs show the effects
of METH on transcript levels for (A) c-fos, (B) fosb, (C) c-jun, (D) junB, (E) Crf, (F) Nmu, (G) Cck, and (H) Npas4 mRNA levels at various time points after
injection of the drug. The rats were injected with a single injection of METH as described in the method section. Total RNA was extracted from the
NAC and used in qPCR assays. The relative amounts of transcripts were normalized to OAZ1 (ornithine decarboxylase antienzyme 1). Statistical
significance was determined by ANOVA followed by post-hoc tests. Key to statistics (n=5–8 animals per group): *=p,0.05; **=p,0.01;
***=p,0.001, in comparison to the control group.
doi:10.1371/journal.pone.0034236.g003
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e34236Figure 4. METH induced significant decreases in H3K9 and
H3K18 acetylation in the NAC. The graphs show representative
results from Western blot analyses using specific antibodies against (A)
H3K9ac and H3K18ac (C) at various time points after injection of the
drug. The rats were injected with a single injection of METH as
described in the method section. Western blot analyses were carried
out as described in the Method section. The relative amounts of
proteins were normalized to tubulin. The bar graphs show quantifica-
tion of the effects of METH on (B) H3K9ac and (D) H3K18ac, respectively.
Statistical significance was determined by ANOVA followed by post-hoc
tests. Key to statistics (n=6 rats per group): *=p,0.05; **=p,0.01;
***=p,0.001, in comparison to the control group.
doi:10.1371/journal.pone.0034236.g004
Figure 5. METH caused significant increases in H4K5 and H4K8
acetylation in the NAC. The graphs show representative results from
Western blot analyses using specific antibodies against (A) H4K5ac and (C)
H3K18 at various time points after injection of the drug. The rats were
injected with a single injection of METH as described in the method section.
Western blot analyses were carried out as described in the Method section.
The relative amounts of proteins were normalized to tubulin. The bar
graphs show quantification of the effects of METH on (B) H4K5ac and (D)
H4K8ac, respectively. Statistical significance was determined by ANOVA
followed by post-hoc tests. Key to statistics (n=6 rats per group):
*=p,0.05; **=p,0.01; ***=p,0.001, in comparison to the control group.
doi:10.1371/journal.pone.0034236.g005
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also shown to induce CRF receptor-dependent hyperlocomotion
[43]. Importantly, Moffett and Goeders (2007) [44] recently
reported that CP-154–526, a CRF type-1 receptor antagonist, was
able to attenuate METH-induced reinstatement of extinguished
METH-seeking behaviors in the rat. The METH-induced
increases in CRF expression might be related to the fact that the
drug injection caused downregulation of HDAC1 expression in
the nuclear fraction of the NAC since HDAC1 up-regulation has
been reported to cause downregulation of CRF expression [45].
In contrast to the METH-increases in Crf mRNA levels, we
found substantial decreases in Cck mRNA levels that lasted
through the duration of the experiments. The neuropeptide, CCK,
is synthesized as a pre-pro-hormone that is cleaved to produce
several peptides [46] including the main neurotransmitter, CCK-
8, which is involved in a number of behavioral and biological
functions [47]. CCK is widely distributed in the rodent brain
[48,49] and co-localizes with several neurotransmitters including
dopamine [50,51]. CCK is located within vesicles [49] from which
it can be released [52]. There also exists an interesting literature
on the role of CCK on dopamine-mediated behaviors, with
different subregions of the NAC showing differential effects on
DA-mediated locomotor activity [53]. For example, Crawley et al.
(1985) [54] reported that injection of DA into the NAC caused
dose-dependent increases in locomotor activity. Injection of CCK
alone had no effects on locomotor responses. However, co-
administration of CCK with DA potentiated DA-induced
hyperlocomotion. Subsequent studies revealed involvement of
CCK-A and CCK-B receptors in the mediation of DA-induced
hyperlocomotion in the medial posterior NAC and anterior NAC,
respectively [55]. On the other hand, Weiss et al., (1988) [56]
reported that injections of CCK into the NAC antagonized
amphetamine-induced hyperlocomotion. CCK also antagonized
apomorphine-induced hyperlocomotion [57]. Nevertheless, our
observations of METH-induced decreases in Cck mRNA levels
suggest that injection of METH might have caused co-release of
CCK and DA from midbrain projections to the NAC [50] and
that local CCK-containing cell bodies [48,49] might have
compensated to the overstimulation of CCK receptors by
decreasing Cck transcript levels. This idea is consistent with the
report that amphetamine caused DA release that was accompa-
nied with a rapid and transient CCK release in the NAC with a
peak response within the first 20 min after the drug injection [58].
The timing of the AMPH-induced release of CCK is consistent
with the decreases in Cck mRNA levels and with the suggested
possibility that the observed decreased Cck transcript levels are
potentially compensatory to METH-induced CCK release. Our
results are also consistent with the report that a single dose of a
lower dose of METH (0.5 mg/kg) [59] or daily METH injections
for 14 days [60] caused decreases in Cck mRNA levels in the rat
brain.
The accumulated evidence indicates that increases in gene
expression are associated with increases in histone acetylation
whereas decreases in gene expression correlate with hypoacetyla-
tion of histones [61,62]. Histone H4 acetylation enables regulatory
proteins to access DNA and plays a major role in regulating gene
expression [63,64]. The substantial METH-induced increases of
histone H4K5 and H4K8 acetylation are, thus, of interest because
both H4K5 and H4K8 belong to the class of so-called ‘‘common
modification module’’ that is present on active and poised
promoters [65], thus suggesting that METH might have
influenced the composition of this module. The increases in
H4K5 and H4K8 acetylation might be secondary to the METH-
induced increases in the expression of ATF2 that has HAT activity
[66] for histone 4 [28]. ATF-2 is a member of the ATF/CREB
family of transcription factors that contain a common basic region
leucine zipper (bZIP) [67]. The family members that include
Figure 6. METH induced differential changes in the expression
of (A) pCREB and (B) ATF2 in the NAC. The graphs show
representative results from Western blot analyses using specific
antibodies against (A) pCREB and (C) ATF2 at various time points after
injection of the drug. Western blot analyses and statistical analyses
were carried out as described above. The relative amounts of proteins
were normalized to tubulin. The bar graphs show quantification of the
effects of METH on (B) pCREB and (D) ATF2, respectively. Key to
statistics (n=6 rats per group): *=p,0.05; **=p,0.01; ***=p,0.001,
in comparison to the control group.
doi:10.1371/journal.pone.0034236.g006
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homodimerize or heterodimerize with members of other bZIP-
containing proteins including members of the AP1 family of
transcription factor [68]. ATF-2 itself, can heterodimerize with c-
Jun [69] and c-Fos [70]. ATF-2 has been shown to bind to both
the AP-1 site (TGACTCA) and the CRE site (TG/AACGTCA)
[68,71]. As mentioned above, ATF-2 possesses intrinsic histone
acetyltransferase (HAT) activity on histone H4 and promotes
CRE-dependent transcription [72]. A potential role for ATF2 in
METH-induced H4 acetylation is consistent with our findings that
the increases in ATF2 preceded H4K5 and H4K8 acetylation
after the METH injection. Because ATF2 HAT activity has been
shown to be necessary for CRE-dependent transcription [72], it is
fair to propose that the delayed increases in gene expression after a
single injection of METH might be due, in part, to increases in
H4K5 and H4K8 acetylation secondary to METH-induced
increases in ATF2 expression. It is important to note that the
METH-induced increased in H4K5 acetylation could also be due
to the drug-induced decreases in HDAC1 expression observed in
the nuclear fractions obtained from the NAC because RNAi-
mediated reduction in HDAC1 nuclear staining was reported to
induce increases in H4K5 acetylation [73]. The authors also
reported that RNAi-induced decreases in HDAC1 expression
were accompanied by increased HDAC2 expression, which we
also observed after the single injection of METH (Fig. 7C).
Although the specific role for ATF2, HDAC1, and H4K5ac in the
regulation of specific target genes will have to depend on future
studies using chromatin precipitation followed by massive parallel
sequencing (ChIP-Seq) in order to provide genome-scale quanti-
fication of ATF2- and HDAC1-, and H4K5ac-DNA binding
[24,25], these investigations are beyond the scope of the present
paper. Nevertheless, it is notable that some known ATF2 target
genes including c-fos and c-jun [74,75] did show METH-induced
increases (see Figure 3B and 3C, respectively). Similarly, CRF
whose expression is downregulated by increased HDAC1
expression [45] showed significant increases (Fig. 3E) after the
METH injection that caused decreases in HDAC1 expression in
the nuclear fraction of the NAC (see Fig. 7A). These caveats,
notwithstanding, our present observations provide additional
support for the proposal that changes in gene regulation that
occur after exposure to illicit substance such as cocaine might be
consequences of alterations in histone modifications [76,77].
Future studies in this laboratory will seek to determine the role
of specific histone modifications in acute and chronic METH-
induced changes in gene expression in the brain.
Our experiments also showed that METH caused substantial
time-dependent decreases in the acetylation of histone H3K9,
H3K18, and H4K16. These changes in histone acetylation are
consistent with our demonstration that METH also caused
substantial increases in HDAC2 protein levels in the NAC. Indeed,
recruitment of HDAC proteins to the promoters of genes is known
to cause histone hypoacetylation and subsequent transcriptional
repression of various genes [78,79], including neuronal genes
[80,81]. Therefore, the observed METH-induced histone hypoa-
cetylation in H3K9 and H3K18 might offer a partial explanation
for the METH-induced repression of many genes observed at 8, 16,
and24 hrsafterthesingleMETHinjection,withalargernumberof
genes being down-regulated than up-regulated at the 8-hr, 16-hr
and 24-hr time points. Although previous studies have focused
mainly on the role of the cAMP/PKA/CREB pathway [82] in
psychostimulant-induced changes in gene expression [11], the
present study identifies increases in HDAC2, but decreased
H3K9ac and H3K18ac expression as potentially effectors of
METH-induced repression of genes that were affected both early
and late during the course of the present experiments. This idea is
consistent with the report that HDAC inhibition caused potentia-
tion of kainate-induced increases in c-fos and c-jun expression [83].
Finally, the greater number of repressed genes observed at the 24-hr
time point might be due, in part, to the concomitant METH-
induced decreases in pCREB expression that occurred at that time.
Figure 7. Differential METH-induced changes in the expression
of (A) HDAC1 and (B) HDAC2 in the NAC. The graphs show
representative results from Western blot analyses using specific
antibodies against (A) HDAC1 and (C) HDAC2 at various time points
after injection of the drug. Western blot analyses and statistical analyses
were carried out as described above. The relative amounts of proteins
were normalized to tubulin. The bar graphs show quantification of the
effects of METH on (B) HDAC1 and (D) HDAC2, respectively. Key to
statistics (n=6 rats per group): *=p,0.05; **=p,0.01; ***=p,0.001,
in comparison to the control group.
doi:10.1371/journal.pone.0034236.g007
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concomitant increases and decreases in the expression of many
genes in the rat NAC after a single METH injection. These
changes in gene expression were associated with diverse alterations
in histone acetylation. These observations are consistent with
previous demonstrations that histone modifications can participate
in cross-talks [84,85] that regulate gene expression in a complex
fashion [65,86,87]. Our findings also suggest that studies of the
effects of psychostimulants need to take into consideration the
combinatorial roles of histones in their control of gene expression
[65]. Our study also supports the notion that modulators of histone
acetylation might be attractive therapeutic players against various
diseased states including addiction to licit and illicit substances.
Although more studies are needed to determine the specific
manner by which METH-induced changes in ATF2, HDACs,
and histone acetylation might differentially influence the levels of
specific transcripts, our data suggest that a single METH exposure
can cause profound alterations in the molecular machinery of the
brain. Finally, even though the present study aimed to provide an
initial look at the effects of METH on histone acetylation, future
studies will investigate the effects of the drug on other histone
modifications because understanding the molecular impact of
these combinatorial alterations might lead to better therapeutic
strategies against the adverse effects of psychostimulant use.
Materials and Methods
Animals and Drug treatment
Male Sprague-Dawley rats (Charles River Labs, Raleigh, NC,
USA), weighing 375625 g, were used in the experiments. Rats
were housed in a temperature-controlled (22.2+0.2uC) room with
free access to food and water. The animals received a single
injection of METH (20 mg/kg) and were euthanized at various
time points afterwards. This METH dose has been used in
behavioral and biochemical experiments and has been shown
robust increases in DA release in the NAC [6] (6). All animal use
procedures were according to the NIH Guide for the Care and
Use of Laboratory Animals and were approved by the National
Institute of Drug Abuse-/Intramural Research Program (IRP)
Animal Care and Use Committee (NIDA/IRP-ACUC).
Tissue collection and RNA extraction
At the indicated time after the METH or saline injections, rats
(n=5 per group) were euthanized and the NAC was dissected and
immediately put on dry ice. Total RNA was isolated from the
nucleus accumbens according to the manufacturer’s manual using
Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA
integrity was detected using an Agilent 2100 Bioanalyzer (Agilent,
Palo Alto, CA, USA).
Microarray hybridization and data analysis
Microarray hybridization was carried out using RatRef-12
Expression BeadChips arrays (22, 523 probes) (Illumina Inc., San
Diego, CA) essentially as previously described by us [13,88]. Raw
data were imported into GeneSpring and normalized using global
normalization. The normalized data were used to identify changes
in gene expression at the different time points (1, 2, 4, 8, 16 and
24 hr) after the injection of METH. A gene was identified as
significantly affected if it showed increased or decreased expression
according to an arbitrary cut-off of 1.7-fold changes at p,0.05,
according to the GeneSpring statistical package. Similar criteria
have been successfully used in our previous microarray studies
[13,88,89]. Network analyses were performed using the Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems, Redwood
City, CA). The IPA software allows for the identification of
networks, canonical pathways, and biological functions that are
affected by the drug. We also used the IPA software to graphically
show the cellular location of genes significantly affected by METH
and to overlay differentially affected networks of interest.
Quantitative polymerase chain reaction (qPCR)
Total RNA was reverse-transcribed to cDNA with oligo dT
primer using Advantage RT for PCR kits (BD Biosciences
Clontech Laboratories, Palo Alto, CA, USA). Gene-specific
primers were generated using Light Cycler Probe Design software
and synthesized by the Synthesis and Sequencing Facility of Johns
Hopkins University (Baltimore, MD, USA). Real-time PCR
experiments were performed using iQ SYBR Green supermix
(Bio-Rad Laboratories, Hercules, CA) and Chromo 4 Detector
(MJ Research, Inc. Waltham, MA. For all qPCR experiments,
individual data (n=5–8 per group) were normalized using the
corresponding OAZ1 signal as described [90].
Western Blot Analysis
Western blot analyses were carried out essentially as previously
described by our laboratory [13]. The antibodies used were anti-
acetyl-histone H4K8 (Lys 8), H4K12 (Lys 12), and H4K16 (Lys
16) (Millipore, Billirica, MA, USA); anti-HDAC1 and anti-
HDAC2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA); anti-phospho-CREB and anti-ATF2 (Cell Signaling
Technology, Danvers, MA, USA). To confirm equal protein
loading, blots were re-probed with a-tubulin antibody (1:4000;
Sigma, 2 h at RT). LumiGLO chemiluminescent reagents (Cell
Signaling Technology Inc., Danvers, MA, USA) were used to
detect protein expression. Signal intensity was measured densito-
metrically with LabWorks version 4.5 (BioImaging Systems
analysis software, BioImaging System, UVP Inc., Upland, CA).
For quantification, the signal intensity was normalized using the
signal intensity of tubulin (n=6 per group).
Statistical Analyses
Data for quantitative PCR and Western blot analyses are
presented as means 6 SEM. Statistical analyses were performed
using one-way ANOVA analysis followed by Fisher’s protected
least significant difference (StatView 4.02, SAS Institute, Cary,
NC). Criteria for significance were set at p#0.05.
Supporting Information
Figure S1 A network of genes whose expression was
affected by METH at 8-hr after the injection of the drug.
Networks of related genes were identified using Ingenuity Pathway
Analysis (IPA) software. The figure shows a network of affected
genes that are involved in lipid metabolism, molecular transport,
and cellular compromise and cell death. Color schemes are as
described in figure 2.
(PPT)
Figure S2 A network of genes whose expression was
affected by METH at 16-hr after the injection of the
drug. Networks of related genes were identified using Ingenuity
Pathway Analysis (IPA) software. The figure shows a network of
genes that participate in cellular development, cellular growth and
nervous system development. Relationships are shown as lines and
arrows. Color schemes are as described in figure 2.
(PPT)
Figure S3 A network of genes whose expression was
affected by METH at 24-hr after injection of the drug.
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e34236Networks of related genes were identified using Ingenuity Pathway
Analysis (IPA) software. The figure shows genes involved in the
regulation of cell death, nervous system development, and cell
proliferation. Relationships are shown as lines and arrows. Color
schemes are as described in figure 2.
(PPT)
Figure S4 METH administration caused significant
decreases in H4K16 acetylation in the NAC. The graph
shows representative results from Western blot analyses using a
specific antibody against (A) H4K16ac at various time points after
the injection of the drug. Western blot analyses and statistical
analyses were carried out as described in Fig. 4. The bar graph
shows quantification of the effects of METH on H4K16ac. Key to
statistics: *=p,0.05; **=p,0.01; ***=p,0.001, in comparison
to the control group.
(PPT)
Table S1 Partial list of METH-upregulated genes
measured at 1-hr after the drug injection. The list of
genes was generated as described in the text. The genes are listed
in descending order according to METH-induced fold changes in
transcript levels.
(DOC)
Table S2 Partial list of METH-regulated genes mea-
sured at 8-hr after the drug injection. The genes are listed in
descending order according to METH-induced fold changes in
gene expression at the 8-hr. time point. The values for the 16- and
24-hr time points are listed for comparison.
(DOC)
Table S3 Partial list of METH-regulated genes mea-
sured at 16-hr after the drug injection. The genes are listed
in descending order according to METH-induced fold changes in
gene expression at the 16-hr. time point. The values for the 8- and
24-hr time points are listed for comparison.
(DOC)
Table S4 Partial list of METH- regulated genes mea-
sured at 24-hr after the drug injection. The genes are listed
in descending order according to METH-induced fold changes in
gene expression at the 24-hr. time point. The values for the 8- and
16-hr time points are listed for comparison.
(DOC)
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